<DOC>
	<DOC>NCT02647112</DOC>
	<brief_summary>Clinical trial to determine the performance characteristics (sensitivity and specificity) of the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology.</brief_summary>
	<brief_title>Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma</brief_title>
	<detailed_description>Clinical trial to determine the performance characteristics (sensitivity and specificity) of the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology in patients under monitoring for reccurrence of bladder cancer.</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Transitional Cell</mesh_term>
	<criteria>Patient diagnosed with incident or recurrent urothelial cell carcinoma and undergoing surveillance monitoring for urothelial cell carcinoma Has all urothelial cell carcinoma tumor resected within the past 12 months Has a plan for cystoscopic surveillance Planning to undergo radical cystectomy or chemotherapyradiation for UCC</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Bladder cancer</keyword>
	<keyword>Urine</keyword>
	<keyword>Methylation</keyword>
</DOC>